Majesty Therapeutics is an early-stage biotechnology company founded in 2024 and based in the Lauderdale-by-the-Sea area of Florida. It describes itself as transforming vascular and fibrotic disease through targeted biology, and its LinkedIn and PitchBook profiles frame the work as precision medicine for immune-mediated diseases. The company is operating in stealth: its website is a placeholder and no pipeline candidate or mechanism has been disclosed publicly. Its May 2026 Form D states that proceeds will fund research and development, trial design and regulatory filings, manufacturing, and working capital, and names Shawn Titcomb as chief executive and Ankit Bhargava as acting chief scientific officer.